You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Colorcon
Merck
AstraZeneca
Harvard Business School

Last Updated: February 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 5,317,016


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,317,016
Title: Pyrrolidylthiocarbapenem derivative
Abstract:A pyrrolidylthiocarbapenem derivative represented by Formula I is provided: ##STR1## wherein R.sup.1 is hydrogen or lower alkyl; R.sup.2, R.sup.3 and R.sup.4 are hydrogen, lower alkyl which can be substituted or an amino protecting group independently, or R.sup.2 and R.sup.3 together with a nitrogen atom to which R.sup.2 and R.sup.3 are bonded form a saturated or unsaturated cyclic group, or R.sup.2 and R.sup.4, or R.sup.3 and R.sup.4 together with two nitrogen atoms and one sulfur atom in the sufamide group form a saturated or unsaturated cyclic group; each cyclic group can further include at least one atom selected from the group consisting of oxygen, sulfur and nitrogen, and each cyclic group can be substituted; X.sup.1 is hydrogen or a hydroxy protecting group; X.sup.2 is hydrogen, a carboxy protecting group, an ammonio group, an alkali metal or an alkaline-earth metal; and Y.sup.2 is hydrogen or an amino protecting group.
Inventor(s): Nishitani; Yasuhiro (Osaka, JP), Irie; Tadashi (Osaka, JP)
Assignee: Shionogi Seiyaku Kabushiki Kaisha (Osaka, JP)
Application Number:07/929,961
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 5,317,016

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,317,016

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan3-207972Aug 20, 1991
Japan4-35366Feb 21, 1992

International Family Members for US Patent 5,317,016

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 147726   Start Trial
Austria 201413   Start Trial
Australia 2109092   Start Trial
Australia 652273   Start Trial
Canada 2076430   Start Trial
Canada 2203942   Start Trial
China 1032257   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Dow
Moodys
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.